Press Releases

11.02.2015

New Data Continue to Characterize the Safety and Efficacy of XELJANZ® (tofacitinib citrate) in the Treatment of Rheumatoid Arthritis

10.29.2015

GLYCOMIMETICS, INC. ANNOUNCES INITIATION OF FIRST CLINICAL TRIAL EVALUATING SUBCUTANEOUS ADMINISTRATION OF RIVIPANSEL

10.29.2015

HALOZYME ANNOUNCES FIRST CLINICAL DOSING OF PFIZER’S RIVIPANSEL USING ENHANZE™TECHNOLOGY

10.29.2015

Announcement Regarding Allergan plc

10.29.2015

Pfizer Announces Collaboration with GSK on Next-Generation Design of Portable, Continuous, Miniature and Modular (PCMM) Oral Solid Dose Development and Manufacturing Units

10.27.2015

PFIZER REPORTS THIRD-QUARTER 2015 RESULTS

10.19.2015

Pfizer’s Inotuzumab Ozogamicin Receives FDA Breakthrough Therapy Designation for Acute Lymphoblastic Leukemia (ALL)

10.14.2015

Pfizer Receives Complete Response Letter from FDA for Oral XELJANZ® (tofacitinib citrate) Supplemental New Drug Application for Moderate to Severe Chronic Plaque Psoriasis

10.13.2015

Pelago Bioscience grants Pfizer Inc. license to the CETSA™ method

10.13.2015

Pfizer and the Union for International Cancer Control Award 20 Grants Totaling $760,000 to Address the Needs of Metastatic Breast Cancer Patients Worldwide

10.09.2015

Pfizer’s Phase 2 Study Demonstrates Safety, Tolerability and Immunogenicity of TRUMENBA® When Coadministered with Meningococcal A, C, Y and W-135 Polysaccharide Conjugate (MCV4) and Tetanus, Diphtheria and Pertussis (Tdap) Vaccines in Adolescents

10.07.2015

Merck KGaA, Darmstadt, Germany, and Pfizer Announce Investigational Immunotherapy Avelumab Receives FDA Fast Track Designation for Metastatic Merkel Cell Carcinoma